General Secretary To Lam witnessed the handover ceremony of cooperation documents between VNVC and GSK in the UK.

On the afternoon of October 30, in London, Vietnam Vaccine Company VNVC and GSK Vietnam, part of the GSK - UK biopharmaceutical group, exchanged documents to upgrade strategic cooperation on access to new drugs and vaccines, scientific research and exchanges on vaccine production.

The signing ceremony was witnessed by General Secretary To Lam and the UK Government's Trade Envoy, Matt Western. The event took place within the framework of General Secretary To Lam's official visit to the United Kingdom and Northern Ireland and the upgrading of Vietnam-UK relations to a Comprehensive Strategic Partnership.

General Secretary To Lam and UK Government Trade Envoy Matt Western witnessed the exchange of documents elevating cooperation between Mr. Ngo Chi Dung, Chairman and CEO of Vietnam Vaccine Company (VNVC), and Ms. Kaja Natland, Senior Vice President of GSK Asia Pacific , International Region. Photo: HTN

According to the agreement, VNVC and GSK will cooperate to accelerate access to advanced medicines and vaccines developed by GSK, especially to bring new specialized drugs and vaccines produced at GSK's modern, strategically located global factories in Worthing and Barnard Castle (UK) to Vietnam as soon as possible. In addition, the two sides will also cooperate in scientific research and exchange experiences in vaccine production so that VNVC can independently produce and supply vaccines at its factory in Vietnam.

In particular, VNVC Vietnam is very interested in accessing new vaccines, antibiotics, and next-generation cancer drugs that GSK is producing.

The signing is expected to open up collaboration opportunities worth an estimated £500 million (approximately VND 17 trillion) over the next five years, while also boosting clinical research cooperation and the exchange of knowledge and best practices in vaccine production.

The cooperation agreement between VNVC and GSK focuses on increasing early access to new medicines and vaccines for the Vietnamese people, while also promoting scientific research and exchange on vaccine production. Photo: Ha Ngan

At the document exchange ceremony within the framework of the Vietnam-UK High-Level Economic Conference, General Secretary To Lam outlined three key areas of cooperation between Vietnam and the United Kingdom in the new era. Accordingly, the first focus is to promote research and development (R&D) cooperation between universities and research institutes of businesses in both countries specializing in applied research on artificial intelligence (AI), big data, smart energy, healthcare, chemical engineering, and strategic transformative technologies. Secondly, to strengthen investment and exchange of high-level experts, promoting the development of AI applications and digital transformation in key economic sectors. Thirdly, to support businesses in both countries in expanding investment, sharing data, and implementing comprehensive technology cooperation programs.

The General Secretary affirmed that Vietnam is ready to be a reliable partner of the United Kingdom in technological development and innovation, bringing practical value to the people of both countries and making positive contributions to the region and the world. The two governments will also strengthen coordination and encourage various forms of cooperation, research, training, and technology transfer, contributing to further deepening the comprehensive strategic partnership between Vietnam and the UK.

Previously, in October 2025 in Ho Chi Minh City, with the presence of the Deputy Consul General of the United Kingdom in Ho Chi Minh City, Vietnam Vaccine Company (VNVC), Tam Anh General Hospital System, and GSK Vietnam Pharmaceutical Company held a high-level working program and signed a memorandum of cooperation on access to new drugs and vaccines, promoting clinical research, and exchanging knowledge in vaccine production.

The signing ceremony of the Memorandum of Strategic Cooperation between VNVC, Tam Anh, and GSK took place in Ho Chi Minh City in October 2025, witnessed by the Deputy Consul General of the United Kingdom in Ho Chi Minh City, William Lawrenson. Photo: Thanh Luan

This document signing ceremony in London is a testament to the strengthening and upgrading of the strategic cooperation between the parties before the high-level leaders of both countries, aiming to improve the quality of healthcare for the Vietnamese people from prevention to treatment, contributing to realizing the aspiration of building Vietnam into a regional center for research, development, application, and innovation in biopharmaceutical technology.

Mr. Ngo Chi Dung, Chairman and CEO of Vietnam Vaccine Company (VNVC) and VNVC Vaccine and Biological Products Factory, stated that VNVC and GSK have established a comprehensive strategic partnership, coordinating the introduction of many new generation vaccines to Vietnam, significantly contributing to ending the vaccine shortage for children and adults in Vietnam.

Over the past five years, the VNVC - Tam Anh healthcare ecosystem has collaborated with GSK on commercial activities, healthcare personnel training, and other initiatives, valued at nearly £400 million (over VND 13 trillion) and continuing to grow annually. Along with the development of the VNVC Vaccination System, GSK vaccines have become widely available and hold a leading market share among pharmaceutical companies in Vietnam's market of over 100 million people.

Mr. Ngo Chi Dung emphasized: "Elevating cooperation helps Vietnam address issues related to vaccine supply through trade cooperation, proactively accessing advanced biopharmaceutical products such as new antibiotics, new cancer drugs, and especially accessing knowledge in vaccine production so that Vietnam can move towards self-sufficiency in domestic production and supply, and export."

The VNVC Vaccine and Biological Products Factory, with an initial investment of over 2.5 trillion VND in Tay Ninh province, will utilize state-of-the-art global technologies and commence construction in May 2025. (Photo: VNVC)

Ms. Kaja Natland, Senior Vice President of GSK Asia Pacific, International Region, said: “The strategic partnership with VNVC in the coming years plays a key role in expanding access to world-class advanced healthcare solutions such as specialty drugs, oncology drugs, effectively implementing lifelong immunization programs and promoting clinical research. GSK aims to work with VNVC to achieve the shared goal of creating a positive impact on the health of more than one-third of Vietnam's population in the next five years, in line with GSK's mission of uniting science, technology and talent to conquer disease.”

Over the past nearly 10 years, VNVC has brought many new, next-generation vaccines to Vietnam, including some of GSK's leading products, helping to protect the health of millions of children and families. Photo: Dieu Thuan

This strategic partnership between VNVC and GSK in the UK is also of significant importance at the present time, demonstrating the remarkable development and upgrading of the relationship between private enterprises representing the two countries in leveraging breakthrough policy incentives on international cooperation, investment in science and technology development, the private economy, and strengthening public health care as directed by the Politburo, the Government, and the Ministry of Health of Vietnam.

Source: https://daibieunhandan.vn/tong-bi-thu-to-lam-chung-kien-le-trao-van-kien-hop-tac-giua-vnvc-va-gsk-tai-anh-10393731.html